6-Feb-2026
Business Wire (Sat, 31-Jan 10:41 PM ET)
Globe Newswire (Mon, 12-Jan 3:31 PM ET)
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Globe Newswire (Fri, 2-Jan 8:00 AM ET)
Globe Newswire (Thu, 18-Dec 4:54 PM ET)
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
Globe Newswire (Mon, 24-Nov 8:30 AM ET)
Globe Newswire (Mon, 10-Nov 3:29 PM ET)
Globe Newswire (Mon, 10-Nov 11:43 AM ET)
Business Wire (Mon, 10-Nov 11:20 AM ET)
PRNewswire (Mon, 10-Nov 8:45 AM ET)
Globe Newswire (Sun, 9-Nov 8:50 AM ET)
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Lantheus Holdings trades on the NASDAQ stock market under the symbol LNTH.
As of February 6, 2026, LNTH stock price climbed to $64.89 with 801,626 million shares trading.
LNTH has a beta of 0.53, meaning it tends to be less sensitive to market movements. LNTH has a correlation of 0.03 to the broad based SPY ETF.
LNTH has a market cap of $4.30 billion. This is considered a Mid Cap stock.
Last quarter Lantheus Holdings reported $384 million in Revenue and $1.27 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.09.
In the last 3 years, LNTH traded as high as $126.89 and as low as $47.25.
The top ETF exchange traded funds that LNTH belongs to (by Net Assets): VTI, IJH, IWM, VB, AVUV.
LNTH has underperformed the market in the last year with a price return of -28.6% while the SPY ETF gained +15.1%. However, in the short term, LNTH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.9% vs +3.3% return in SPY. But in the last 2 weeks, LNTH shares have been beat by the market, returning -3.9% compared to an SPY return of +0.2%.
LNTH support price is $63.49 and resistance is $66.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNTH shares will trade within this expected range on the day.